Immutep's Efti Demonstrates Promising Survival Data in Lung Cancer Trial
IMM (IMM) Share Update November 2024 Wednesday 13th
Immutep's Efti Shows Promising Results in Lung Cancer Trial
Immutep Limited has announced highly encouraging results from its INSIGHT-003 Phase I trial, showing significant survival benefits for lung cancer patients treated with eftilagimod alpha (efti) in combination with pembrolizumab and chemotherapy.
Instant Summary:
- Median Overall Survival (OS) of 32.9 months in trial patients.
- Median Progression-Free Survival (PFS) of 12.7 months.
- 24-month Overall Survival rate of 81.0%.
- Significant improvement in Overall Response Rate (ORR) compared to historical controls.
- Favorable safety profile with no new safety signals.
INSIGHT-003 Trial Results
The INSIGHT-003 trial, conducted by Immutep Limited, has shown promising results in the treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) using a combination of eftilagimod alpha (efti), pembrolizumab (KEYTRUDA®), and chemotherapy. The trial's mature data reveals a median Overall Survival (OS) of 32.9 months and a median Progression-Free Survival (PFS) of 12.7 months, far exceeding historical controls.
Furthermore, the 24-month Overall Survival rate stands at an impressive 81.0%, showcasing the potential of this combination therapy to significantly improve patient outcomes. The data also indicates a substantial improvement in the Overall Response Rate (ORR) across all levels of PD-L1 expression, with a 75.0% ORR in patients with high PD-L1 expression, 58.8% in those with low PD-L1 expression, and 47.4% in patients with negative PD-L1 expression.
Safety and Future Prospects
The safety profile of the combination therapy remains favorable, with no new safety signals reported. This underscores the potential of efti as a safe addition to the standard-of-care treatment for NSCLC. As the INSIGHT-003 trial nears completion of patient enrollment, further data updates are anticipated in 2025, which could provide additional insights into the long-term efficacy and safety of this treatment approach.
Immutep is also preparing for the upcoming TACTI-004 Phase III trial, which will further evaluate the efficacy of efti in combination with pembrolizumab and chemotherapy, with Progression-Free Survival and Overall Survival as dual primary endpoints.
The positive results from the INSIGHT-003 trial are likely to boost investor confidence in Immutep's innovative cancer therapies. The significant improvement in survival metrics and the favorable safety profile could lead to increased interest from both investors and the medical community. This announcement may positively impact Immutep's stock price as it highlights the potential for efti to become a new standard of care in NSCLC treatment.
Investor Reaction:
Analysts are likely to view these results as a strong indicator of Immutep's potential in the oncology market. The promising survival data and safety profile could lead to increased interest from investors looking for innovative cancer treatment options. However, the final outcomes of the upcoming Phase III trial will be crucial in determining the long-term impact on Immutep's market position.
Conclusion:
Investors should keep a close eye on the upcoming data updates from the INSIGHT-003 trial and the initiation of the TACTI-004 Phase III trial. These developments could play a significant role in shaping Immutep's future and its position in the cancer treatment landscape. Staying informed on these advancements will be key for making informed investment decisions.